The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size has grown exponentially in recent years. It will grow from $10.36 billion in 2024 to $13.32 billion in 2025 at a compound annual growth rate (CAGR) of 28.5%. The growth during the historic period can be attributed to the rising prevalence of transthyretin amyloid cardiomyopathy, an increasing occurrence of transthyretin amyloidosis among geriatric patients, greater awareness among healthcare professionals and patients, as well as improvements in healthcare services and overall awareness.
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size is expected to see exponential growth in the next few years. It will grow to $35.93 billion in 2029 at a compound annual growth rate (CAGR) of 28.2%. The projected growth in the forecast period can be attributed to the increasing prevalence of transthyretin amyloidosis, a rise in the diagnosis of neuropathic disorders, the growing aging population, a higher demand for specific drugs to treat the symptoms of this rare disorder, and an overall increase in healthcare demand. Key trends during this period include the development of new diagnostic technologies, innovative techniques for therapy management, targeted treatments for transthyretin amyloidosis, advancements in diagnostic methods, and improvements in cardiac MRI techniques.
The increasing prevalence of chronic diseases is expected to drive the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. Chronic diseases are long-lasting conditions that progress slowly and can last for a year or more, often requiring ongoing medical care. The rise in chronic diseases is due to factors such as aging populations, sedentary lifestyles, unhealthy diets, rising obesity rates, and exposure to environmental pollutants. Treatment for transthyretin amyloid cardiomyopathy helps stabilize the transthyretin protein, reduce amyloid buildup, improve heart function, and alleviate symptoms, which helps in managing related chronic conditions. For example, in September 2023, the World Health Organization reported that 41 million deaths annually are caused by non-communicable diseases (NCDs) or chronic diseases, accounting for 74% of global deaths. Among these, 17.9 million were due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Therefore, the growing prevalence of chronic diseases is fueling the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are also focusing on developing innovative treatments, such as oral medications to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medications are drugs that are taken by mouth, usually in the form of tablets, capsules, or liquid solutions, as prescribed by a healthcare provider. For instance, in November 2024, BridgeBio Pharma Inc., a U.S.-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Attruby (acoramidis), an oral treatment for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This medication stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have demonstrated that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.
In January 2022, AstraZeneca Plc, a UK-based pharmaceutical company, entered into a partnership with Neurimmune AG, a Switzerland-based biopharmaceutical company. Together, they aim to develop NI006 for the treatment of ATTR-CM, targeting amyloid deposits in the heart. This collaboration seeks to address the growing need for effective treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
Major players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG.
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transthyretin amyloid cardiomyopathy (ATTR-CM) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment involves medical therapies and interventions aimed at managing this progressive, life-threatening condition, which is caused by the accumulation of misfolded transthyretin (TTR) proteins in the heart. This buildup leads to restrictive cardiomyopathy and heart failure.
The main treatment types for ATTR-CM include transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNAi therapy, and other treatments. Transthyretin stabilizers work by preventing the misfolding of transthyretin proteins, thereby reducing amyloid deposits and slowing the progression of the disease. Clinical indications for treatment include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. These treatments are used by various end users, including hospitals, home care settings, specialty clinics, and others.
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report is one of a series of new reports that provides transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market statistics, including the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry global market size, regional shares, competitors with the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market share, detailed transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry. This transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size is expected to see exponential growth in the next few years. It will grow to $35.93 billion in 2029 at a compound annual growth rate (CAGR) of 28.2%. The projected growth in the forecast period can be attributed to the increasing prevalence of transthyretin amyloidosis, a rise in the diagnosis of neuropathic disorders, the growing aging population, a higher demand for specific drugs to treat the symptoms of this rare disorder, and an overall increase in healthcare demand. Key trends during this period include the development of new diagnostic technologies, innovative techniques for therapy management, targeted treatments for transthyretin amyloidosis, advancements in diagnostic methods, and improvements in cardiac MRI techniques.
The increasing prevalence of chronic diseases is expected to drive the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. Chronic diseases are long-lasting conditions that progress slowly and can last for a year or more, often requiring ongoing medical care. The rise in chronic diseases is due to factors such as aging populations, sedentary lifestyles, unhealthy diets, rising obesity rates, and exposure to environmental pollutants. Treatment for transthyretin amyloid cardiomyopathy helps stabilize the transthyretin protein, reduce amyloid buildup, improve heart function, and alleviate symptoms, which helps in managing related chronic conditions. For example, in September 2023, the World Health Organization reported that 41 million deaths annually are caused by non-communicable diseases (NCDs) or chronic diseases, accounting for 74% of global deaths. Among these, 17.9 million were due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Therefore, the growing prevalence of chronic diseases is fueling the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are also focusing on developing innovative treatments, such as oral medications to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medications are drugs that are taken by mouth, usually in the form of tablets, capsules, or liquid solutions, as prescribed by a healthcare provider. For instance, in November 2024, BridgeBio Pharma Inc., a U.S.-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Attruby (acoramidis), an oral treatment for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This medication stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have demonstrated that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.
In January 2022, AstraZeneca Plc, a UK-based pharmaceutical company, entered into a partnership with Neurimmune AG, a Switzerland-based biopharmaceutical company. Together, they aim to develop NI006 for the treatment of ATTR-CM, targeting amyloid deposits in the heart. This collaboration seeks to address the growing need for effective treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
Major players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG.
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transthyretin amyloid cardiomyopathy (ATTR-CM) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment involves medical therapies and interventions aimed at managing this progressive, life-threatening condition, which is caused by the accumulation of misfolded transthyretin (TTR) proteins in the heart. This buildup leads to restrictive cardiomyopathy and heart failure.
The main treatment types for ATTR-CM include transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNAi therapy, and other treatments. Transthyretin stabilizers work by preventing the misfolding of transthyretin proteins, thereby reducing amyloid deposits and slowing the progression of the disease. Clinical indications for treatment include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. These treatments are used by various end users, including hospitals, home care settings, specialty clinics, and others.
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report is one of a series of new reports that provides transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market statistics, including the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry global market size, regional shares, competitors with the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market share, detailed transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry. This transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Characteristics3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends And Strategies4. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market34. Recent Developments In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Growth Analysis And Strategic Analysis Framework
6. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmentation
7. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Regional And Country Analysis
8. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
9. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
10. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
11. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
12. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
13. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
14. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
15. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
16. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
17. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
18. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
19. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
20. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
21. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
22. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
23. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
24. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
25. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
26. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
27. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
28. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
29. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market
30. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape And Company Profiles
31. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Other Major And Innovative Companies
35. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on transthyretin amyloid cardiomyopathy (attr-cm) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for transthyretin amyloid cardiomyopathy (attr-cm) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The transthyretin amyloid cardiomyopathy (attr-cm) treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis; Diflunisal2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
3) By RNAi Therapy: Patisiran; Vutrisiran
4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies
Key Companies Profiled: Pfizer Inc.; Bayer AG.; AstraZeneca Plc; GlaxoSmithKline Plc.; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market report include:- Pfizer Inc.
- Bayer AG.
- AstraZeneca Plc
- GlaxoSmithKline Plc.
- Takeda Pharmaceutical Company Limited
- Novo Nordisk A/S
- Regeneron Pharmaceuticals Inc.
- MedStar Health Inc
- Alnylam Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc.
- Akcea Therapeutics Inc
- BridgeBio Pharma Inc.
- Prothena Corporation plc
- Intellia Therapeutics Inc.
- Alexion Pharmaceuticals Inc.
- Neurimmune Holding AG
- SOM Biotech S.L
- Corino Therapeutics Inc
- Eidos Therapeutics Inc
- CRISPR Therapeutics AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | January 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 13.32 Billion |
| Forecasted Market Value ( USD | $ 35.93 Billion |
| Compound Annual Growth Rate | 28.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
